CARO PHARMA

CARO PHARMA has been active since 2008 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €154,269 and a net result of -€26,056. Equity is growing by about 3.9% per year across the filed financial years. Its solvency ranks better than 44% of 22,576 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 0.2% (very low).